Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 104,384 Shares

Posted by admin on May 26th, 2023

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) major shareholder Endurance (Cayman) Ltd Svf sold 104,384 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $26.15, for a total value of $2,729,641.60. Following the sale, the insider now owns 17,178,585 shares in the company, valued at $449,219,997.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

On Monday, May 22nd, Endurance (Cayman) Ltd Svf sold 91,896 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.72, for a total transaction of $2,363,565.12.
On Friday, May 19th, Endurance (Cayman) Ltd Svf sold 91,651 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.38, for a total value of $2,326,102.38.
On Friday, May 5th, Endurance (Cayman) Ltd Svf sold 136 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.10, for a total value of $3,413.60.
On Wednesday, May 3rd, Endurance (Cayman) Ltd Svf sold 83,674 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.51, for a total value of $2,134,523.74.
On Monday, May 1st, Endurance (Cayman) Ltd Svf sold 3,075 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.30, for a total transaction of $77,797.50.
On Monday, April 24th, Endurance (Cayman) Ltd Svf sold 66,038 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.42, for a total transaction of $1,678,685.96.
On Friday, April 21st, Endurance (Cayman) Ltd Svf sold 305,393 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.78, for a total transaction of $7,873,031.54.
On Wednesday, April 19th, Endurance (Cayman) Ltd Svf sold 76,114 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.12, for a total transaction of $1,911,983.68.
On Monday, April 17th, Endurance (Cayman) Ltd Svf sold 10,524 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.06, for a total value of $263,731.44.
On Friday, April 14th, Endurance (Cayman) Ltd Svf sold 9,565 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.11, for a total value of $240,177.15.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $25.77 on Friday. Vir Biotechnology, Inc. has a 1 year low of $18.05 and a 1 year high of $31.78. The firm has a market cap of $3.45 billion, a price-to-earnings ratio of -23.43 and a beta of 0.26. The company has a 50-day moving average of $24.35 and a 200 day moving average of $25.59.

Vir Biotechnology (NASDAQ:VIR – Get Rating) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.20). The business had revenue of $63.00 million for the quarter, compared to analyst estimates of $50.10 million. During the same quarter in the previous year, the business posted $3.93 EPS. The business’s revenue for the quarter was down 94.9% on a year-over-year basis. On average, equities analysts anticipate that Vir Biotechnology, Inc. will post -3.8 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on VIR. TheStreet downgraded shares of Vir Biotechnology from a “c” rating to a “d+” rating in a research note on Thursday, May 4th. SVB Leerink dropped their target price on Vir Biotechnology from $45.00 to $43.00 and set an “outperform” rating for the company in a report on Friday, January 27th. SVB Securities decreased their price objective on shares of Vir Biotechnology from $43.00 to $42.00 in a report on Friday, May 5th. HC Wainwright cut their target price on shares of Vir Biotechnology from $125.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Vir Biotechnology in a research note on Wednesday, April 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Vir Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $49.75.

Institutional Trading of Vir Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in VIR. Signaturefd LLC boosted its holdings in Vir Biotechnology by 1,313.0% in the first quarter. Signaturefd LLC now owns 1,300 shares of the company’s stock worth $30,000 after acquiring an additional 1,208 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Vir Biotechnology by 33.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock worth $42,000 after purchasing an additional 456 shares during the last quarter. Captrust Financial Advisors boosted its stake in Vir Biotechnology by 1,270.7% in the 2nd quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock worth $46,000 after purchasing an additional 1,690 shares in the last quarter. Tucker Asset Management LLC purchased a new stake in Vir Biotechnology during the 1st quarter valued at about $46,000. Finally, Fifth Third Bancorp increased its stake in Vir Biotechnology by 97.4% during the 1st quarter. Fifth Third Bancorp now owns 2,169 shares of the company’s stock valued at $50,000 after purchasing an additional 1,070 shares in the last quarter. Hedge funds and other institutional investors own 74.97% of the company’s stock.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.